Cargando…

Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism

The β(3)-agonist mirabegron is thought to induce relaxation of the detrusor muscle, contributing to the improvement of overactive bladder symptoms. There has been recent interest in purposing mirabegron as a medical expulsive therapy drug to improve the passage of smaller kidney stones by relaxing t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Iris, Chess-Williams, Russ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192402/ https://www.ncbi.nlm.nih.gov/pubmed/35445849 http://dx.doi.org/10.1007/s00210-022-02244-0

Ejemplares similares

Concentration-dependent alpha(1)-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate
por: Huang, Ru, et al.
Publicado: (2021)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum
por: Wuest, Melinda, et al.
Publicado: (2011)

The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers
por: Batty, Mallory, et al.
Publicado: (2016)

Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice
por: West, Eliza G., et al.
Publicado: (2022)

Effect of α1D-adrenoceptor blocker for the reduction of ureteral contractions
por: Hong, Seong Hwi, et al.
Publicado: (2023)

Histamine modulation of urinary bladder urothelium, lamina propria and detrusor contractile activity via H1 and H2 receptors
por: Stromberga, Zane, et al.
Publicado: (2019)

β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition
por: Zhao, Lin, et al.
Publicado: (2022)

Prostaglandin E2 and F2alpha Modulate Urinary Bladder Urothelium, Lamina Propria and Detrusor Contractility via the FP Receptor
por: Stromberga, Zane, et al.
Publicado: (2020)

The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α(1)-adrenoceptor
por: Nakladal, D., et al.
Publicado: (2019)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis
por: Cai, Dawei, et al.
Publicado: (2022)

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2021)

The signaling and selectivity of α‐adrenoceptor agonists for the human α2A, α2B and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2022)

Chemically Homogenous Compounds with Antagonistic Properties at All α(1)-Adrenoceptor Subtypes but not β(1)-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs
por: Lu, Youyi, et al.
Publicado: (2023)

Altered uterine contractility in response to β-adrenoceptor agonists in ovarian cancer
por: Modzelewska, Beata, et al.
Publicado: (2016)

Endothelium-Dependent NO-Mediated Vasodilation in Humans is Attenuated by Peripheral α(1)-Adrenoceptor Activation
por: Kamper, Adriaan M, et al.
Publicado: (2005)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2020)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G.W., et al.
Publicado: (2022)

Dexmedetomidine attenuates sevoflurane-induced neurocognitive impairment through α2-adrenoceptors
por: Zhang, Yufeng, et al.
Publicado: (2021)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Norepinephrine modulates wakefulness via α1 adrenoceptors in paraventricular thalamic nucleus
por: Wang, Yan, et al.
Publicado: (2021)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

Evidence that the multiflorine‐derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α(2)‐adrenoceptors in mice
por: Lehner, Zsuzsanna, et al.
Publicado: (2019)

Differential mechanisms of action of the trace amines octopamine, synephrine and tyramine on the porcine coronary and mesenteric artery
por: Koh, Andy Hsien Wei, et al.
Publicado: (2019)

Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)

Mirabegron as a Medical Expulsive Therapy for 5-10 mm Distal Ureteral Stones: A Prospective, Randomized, Comparative Study
por: Abdel-Basir Sayed, Mohamed, et al.
Publicado: (2022)

Norepinephrine Drives Persistent Activity in Prefrontal Cortex via Synergistic α1 and α2 Adrenoceptors
por: Zhang, Zizhen, et al.
Publicado: (2013)

Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT(1A) receptor partial agonism and α(1)-adrenoceptor antagonism
por: Montalbano, Alberto, et al.
Publicado: (2019)

A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms
por: Ciayadi, Tjia Adynata, et al.
Publicado: (2023)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Effect of Flos carthami Extract and α (1)-Adrenergic Antagonists on the Porcine Proximal Ureteral Peristalsis
por: Wu, San-Yuan, et al.
Publicado: (2014)

Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

Three Gaseous Neurotransmitters, Nitric oxide, Carbon Monoxide, and Hydrogen Sulfide, Are Involved in the Neurogenic Relaxation Responses of the Porcine Internal Anal Sphincter
por: Folasire, Oladayo, et al.
Publicado: (2016)

Ureteral Access Sheath Influence on the Ureteral Wall Evaluated by Cyclooxygenase-2 and Tumor Necrosis Factor-α in a Porcine Model
por: Lildal, Søren Kissow, et al.
Publicado: (2017)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

The presence of β(2)-adrenoceptors sensitizes α(2A)-adrenoceptors to desensitization after chronic epinephrine treatment
por: Bawa-Khalfe, Tasneem, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_j58s101gc8iekot5rvfmiba6la